NASDAQ · IRIX
Healthcare · Medical - Devices
$0.90
Down-$0.01 (-0.89%)
Updated Oct 10, 2026, 1:26 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IRIX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
IRIX closed at $0.90 after 20 trading sessions, up 36.06% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $0.83 | $0.9499 | $0.7907 | $0.898 | 712.45K |
| Oct 7, 2026 | $0.6854 | $1.02 | $0.6605 | $0.8783 | 19.76M |
| Oct 6, 2026 | $0.7172 | $0.7343 | $0.68 | $0.68 | 28.18K |
| Oct 5, 2026 | $0.6494 | $0.7398 | $0.6493 | $0.69 | 136.44K |
| Oct 2, 2026 | $0.6201 | $0.645 | $0.6201 | $0.6432 | 24.33K |
| Oct 1, 2026 | $0.62 | $0.6375 | $0.62 | $0.632 | 65.55K |
| Sep 30, 2026 | $0.62 | $0.6351 | $0.62 | $0.63 | 23.17K |
| Sep 29, 2026 | $0.62 | $0.6458 | $0.615 | $0.635 | 44.99K |
| Sep 28, 2026 | $0.635 | $0.6421 | $0.6201 | $0.6201 | 23.17K |
| Sep 25, 2026 | $0.63 | $0.6498 | $0.6202 | $0.625 | 27.84K |
| Sep 24, 2026 | $0.634 | $0.6499 | $0.63 | $0.63 | 34.84K |
| Sep 23, 2026 | $0.6356 | $0.653 | $0.634 | $0.634 | 17.54K |
| Sep 22, 2026 | $0.6699 | $0.6699 | $0.635 | $0.6355 | 12.08K |
| Sep 21, 2026 | $0.662 | $0.67 | $0.643 | $0.643 | 46.13K |
| Sep 18, 2026 | $0.635 | $0.67 | $0.635 | $0.67 | 75.48K |
| Sep 17, 2026 | $0.615 | $0.667 | $0.615 | $0.6517 | 50.71K |
| Sep 16, 2026 | $0.625 | $0.67 | $0.607 | $0.607 | 64.88K |
| Sep 15, 2026 | $0.669 | $0.6699 | $0.6287 | $0.6325 | 56.55K |
| Sep 14, 2026 | $0.65 | $0.6599 | $0.62 | $0.64 | 89.99K |
| Sep 11, 2026 | $0.66 | $0.6738 | $0.6524 | $0.66 | 70.42K |
The latest Smart Investors Daily articles mentioning IRIX.
Company
Market Activity
Research & News
IRIX research
Company profile and research snapshot.
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2024 | Stifel | Hold | — |
| Aug 26, 2022 | Stifel | Hold | — |
| May 12, 2021 | Roth Capital | Buy | — |
| Mar 3, 2021 | Roth Capital | Buy | — |
| Jan 13, 2021 | Roth Capital | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 11, 2025
An independent study demonstrated that retreatment with MicroPulse® transscleral laser technology can safely reduce intraocular pressure in glaucoma patients, with IOP reductions ranging from 25% to 35% across different patient groups.
globenewswire.com · Dec 5, 2025
MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Sidoti Year-End Virtual Investor Conference.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IRIX.
